Your browser is no longer supported. Please, upgrade your browser.
Histogen Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own7.03% Shs Outstand37.20M Perf Week0.64%
Market Cap30.45M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float36.34M Perf Month-8.26%
Income-14.70M PEG- EPS next Q-0.12 Inst Own6.70% Short Float0.48% Perf Quarter-14.67%
Sales1.40M P/S21.75 EPS this Y-133.80% Inst Trans1.92% Short Ratio0.28 Perf Half Y-28.86%
Book/sh0.67 P/B1.08 EPS next Y30.40% ROA-66.50% Target Price- Perf Year-64.95%
Cash/sh- P/C- EPS next 5Y38.00% ROE-93.80% 52W Range0.70 - 2.33 Perf YTD-4.27%
Dividend- P/FCF- EPS past 5Y30.60% ROI-224.50% 52W High-68.82% Beta0.93
Dividend %- Quick Ratio11.80 Sales past 5Y- Gross Margin40.30% 52W Low3.66% ATR0.03
Employees19 Current Ratio11.80 Sales Q/Q-95.40% Oper. Margin- RSI (14)40.55 Volatility3.27% 3.77%
OptionableNo Debt/Eq0.00 EPS Q/Q93.40% Profit Margin- Rel Volume0.25 Prev Close0.72
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume623.05K Price0.73
Recom1.50 SMA20-2.25% SMA50-8.54% SMA200-29.09% Volume153,767 Change0.36%
Aug-31-21 04:05PM  
Aug-16-21 08:00AM  
Aug-11-21 04:05PM  
Jul-29-21 04:05PM  
Jul-28-21 04:05PM  
Jun-30-21 08:00AM  
Jun-22-21 08:00AM  
Jun-09-21 04:01PM  
Jun-07-21 04:05PM  
Jun-03-21 08:00AM  
May-19-21 08:00AM  
May-13-21 04:01PM  
Apr-28-21 04:05PM  
Mar-30-21 08:00AM  
Mar-25-21 04:05PM  
Mar-16-21 08:00AM  
Mar-15-21 08:00AM  
Mar-11-21 04:01PM  
Mar-10-21 04:05PM  
Mar-04-21 04:05PM  
Mar-02-21 08:00AM  
Feb-16-21 08:00AM  
Jan-19-21 04:05PM  
Jan-07-21 09:46AM  
Jan-06-21 08:00AM  
Jan-05-21 04:05PM  
Dec-30-20 10:25PM  
Dec-17-20 08:00AM  
Dec-01-20 08:00AM  
Nov-16-20 04:05PM  
Nov-12-20 08:00AM  
Nov-10-20 04:05PM  
Oct-28-20 04:30PM  
Oct-27-20 08:00AM  
Oct-19-20 08:00AM  
Oct-05-20 08:00AM  
Sep-29-20 08:00AM  
Sep-16-20 08:00AM  
Sep-10-20 08:00AM  
Sep-01-20 04:15PM  
Aug-13-20 04:05PM  
Jul-30-20 04:15PM  
Jul-29-20 04:15PM  
Jul-20-20 04:10PM  
Jul-14-20 05:00AM  
Jun-03-20 08:00AM  
Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pascoe Richard WPresident, CEO & DirectorMar 30Buy1.1420,00022,80030,000Mar 30 06:28 PM
Pascoe Richard WPresident, CEO & DirectorDec 03Buy1.2410,00012,39410,000Dec 07 04:06 PM